<DOC>
	<DOCNO>NCT01091701</DOCNO>
	<brief_summary>This study evaluate safety efficacy intravenous ex vivo culture adult allogenic mesenchymal stem cell patient ischemic cerebral stroke . Patient give single intravenous dose allogenic mesenchymal stem cell 2 million cells/Kg body weight placebo within 10 day stroke . Patients follow till 12 month . Safety evaluate type , number proportion patient adverse event . Efficacy evaluate clinical parameter MRI .</brief_summary>
	<brief_title>Ex Vivo Cultured Adult Allogenic MSCs Ischemic Cerebral Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>Age 20 80 year old MRS equal less 4 . Full functional independence present stroke . Patients include within time frame 10 day acute cerebral ischemic episode . This time period refers date dosing . Neuroimaging examination show ischemic cerebral infarct . CT MRI brain scanning reliably exclude intracranial haemorrhage structural brain lesion mimic stroke ( e.g . cerebral tumour ) Stroke symptoms present least 30 minute improve treatment . Symptoms must distinguishable episode generalize ischemia ( i.e . syncope ) , seizure , migraine disorder . Patients motor weakness follow acute cerebral ischemic episode . Able comply study procedure entire length study Haematological cause stroke Evidence intracranial haemorrhage ( ICH ) CTscan . Severe stroke assess clinically ( e.g . MRS &gt; 4 ) . Subjects unlikely complete infusion investigational product and/or unlikely undergo active medical management period due severe clinical condition Previous intracranial hemorrhage , neoplasm , subarachnoid hemorrhage , arterial venous malformation , intra cranial surgery radiological evidence previous cerebral stroke clinical manifestation . History central nervous system damage ( i.e . neoplasm , aneurysm , intracranial spinal surgery ) Size location cerebral infarct determine . Comatose / clinically unstable Serious , preexist medical condition bleed disorder ( eg . leukopenia , thrombocytopenia ) septicemia , TB , hepatic dysfunction ( &gt; 2.5 time ULN hepatic function test ) renal dysfunction ( Serum creatinine &gt; 2 mg/dl ) . Disease impairment precludes adequate neurological exam Hypo hyperglycaemia sufficient account neurological symptom ; patient exclude blood glucose &lt; 3.0 &gt; 20.0mmol/L . The patient female childbearing potential ( unless certain pregnancy possible ) breast feeding . Patient likely unavailable followup e.g . fix home address Patients evidence life threaten infection life threaten illness ( e.g . advanced cancer ) test positive HIV , Hepatitis B , Hepatitis C VDRL Patient already dependent activity daily live present acute stroke Patients include clinical trial within previous month History neoplasia comorbidity could impact patient 's shortterm survival Previous concomitant treatment immune modulators experimental drug 60 day prior study enrolment Any condition judgment investigator would place patient undue risk Sustained systolic BP &gt; 220 mmHg , &lt; 80mmHg , diastolic BP &gt; 140mmHg &lt; 50 mmHg . Patients contraindicate MRI examination .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Ischemic Cerebral Stroke</keyword>
</DOC>